يعرض 1 - 10 نتائج من 30 نتيجة بحث عن '"Greg Andrew Durm"', وقت الاستعلام: 0.74s تنقيح النتائج
  1. 1
    Association of Immune-Related Adverse Events and Efficacy Outcomes With Consolidation Pembrolizumab After Chemoradiation in Patients With Inoperable Stage III Non–Small-Cell Lung Cancer

    المؤلفون: Nikhil Shukla, Zachary S Meyer, Sandra K. Althouse, Greg Andrew Durm, Nasser H. Hanna

    المصدر: Clinical Lung Cancer. 22:274-281

    مصطلحات موضوعية: Male, 0301 basic medicine, Pulmonary and Respiratory Medicine, Oncology, Cancer Research, medicine.medical_specialty, Lung Neoplasms, medicine.medical_treatment, Pembrolizumab, Disease, Antibodies, Monoclonal, Humanized, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Immune system, Carcinoma, Non-Small-Cell Lung, Internal medicine, medicine, Humans, In patient, Lung cancer, Adverse effect, Aged, Neoplasm Staging, Retrospective Studies, business.industry, Chemoradiotherapy, Immunotherapy, Middle Aged, medicine.disease, Progression-Free Survival, Stage III Non-Small Cell Lung Cancer, Survival Rate, 030104 developmental biology, Immune System Diseases, 030220 oncology & carcinogenesis, Female, business

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5054c933b3aa36b97f7fdb005085f6c5Test
    https://doi.org/10.1016/j.cllc.2020.12.014Test


    أضف إلى المفضلة
  2. 2
    Prognostic Variables Associated With Improved Outcomes in Patients With Stage III NSCLC Treated With Chemoradiation Followed by Consolidation Pembrolizumab: A Subset Analysis of a Phase II Study From the Hoosier Cancer Research Network LUN 14-179

    المؤلفون: Bilal Anouti, Greg Andrew Durm, Sandra Althouse, Nasser H. Hanna

    المصدر: Clinical Lung Cancer. 21:288-293

    مصطلحات موضوعية: Male, 0301 basic medicine, Pulmonary and Respiratory Medicine, Subset Analysis, Cancer Research, Prognostic variable, Lung Neoplasms, Paclitaxel, Phases of clinical research, Pemetrexed, Pembrolizumab, Antibodies, Monoclonal, Humanized, 03 medical and health sciences, Clinical Trials, Phase II as Topic, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, medicine, Adjuvant therapy, Humans, Lung cancer, Aged, Etoposide, Retrospective Studies, Pneumonitis, Univariate analysis, business.industry, Chemoradiotherapy, Prognosis, medicine.disease, Consolidation Chemotherapy, Survival Rate, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Carcinoma, Squamous Cell, Cancer research, Female, Cisplatin, business, Follow-Up Studies

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a305cfaebb4b87307ebd88d95b03603bTest
    https://doi.org/10.1016/j.cllc.2019.06.009Test


    أضف إلى المفضلة
  3. 3
    The shifting paradigm of biomarker-driven care in advanced non-small cell lung cancer (NSCLC)

    المؤلفون: Greg Andrew Durm, Nasser H. Hanna

    المصدر: Translational Lung Cancer Research. 8:539-542

    مصطلحات موضوعية: Oncology, medicine.medical_specialty, education.field_of_study, business.industry, Population, Locally advanced, non-small cell lung cancer (NSCLC), Disease, respiratory system, medicine.disease, Editorial Commentary, Internal medicine, medicine, Biomarker (medicine), business, education, Lung cancer

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::456b794a752bdace314001d40c998150Test
    https://doi.org/10.21037/tlcr.2019.04.04Test


    أضف إلى المفضلة
  4. 4
    CX-072 (pacmilimab), a Probody® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study

    المؤلفون: Manreet Randhawa, Nataliya Uboha, Valentina Boni, Alison L. Hannah, Greg Andrew Durm, Aung Naing, Alexander I. Spira, Hendrik Tobias Arkenau, Mark Stroh, Marta Gil-Martin, Javier Garcia-Corbacho, Elisabeth G.E. de Vries, Johanna C. Bendell, Ferry A.L.M. Eskens, Fiona C Thistlethwaite, Patricia LoRusso, Karen A. Autio, Patrick A. Ott

    المساهمون: Guided Treatment in Optimal Selected Cancer Patients (GUTS)

    المصدر: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
    Journal for immunotherapy of cancer, 9(7):002447. BMC
    Dipòsit Digital de la UB
    Universidad de Barcelona

    مصطلحات موضوعية: Cancer Research, medicine.medical_specialty, CARCINOMA, Immunology, Drug development, Pembrolizumab, Gastroenterology, Desenvolupament de medicaments, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Atezolizumab, Farmacoimmunologia, Internal medicine, medicine, Carcinoma, Immunology and Allergy, 030212 general & internal medicine, Anaplastic thyroid cancer, PEMBROLIZUMAB, RC254-282, Pharmacology, business.industry, Immunopharmacology, Anal Squamous Cell Carcinoma, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, Rash, ATEZOLIZUMAB, ANTIBODY, Oncology, Response Evaluation Criteria in Solid Tumors, SAFETY, 030220 oncology & carcinogenesis, Molecular Medicine, medicine.symptom, business

    وصف الملف: application/pdf

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3669f7e2da60cf1a231de6ed86614bcTest
    http://hdl.handle.net/2445/179966Test


    أضف إلى المفضلة
  5. 5
    Optimal Duration of Maintenance Checkpoint Inhibitor Therapy in Patients With Advanced NSCLC

    المؤلفون: Nikhil Shukla, Greg Andrew Durm, Nasser H. Hanna

    المصدر: JCO oncology practice. 17(8)

    مصطلحات موضوعية: Oncology, medicine.medical_specialty, Lung Neoplasms, Oncology (nursing), business.industry, Health Policy, Immune checkpoint inhibitors, MEDLINE, Text mining, Internal medicine, Carcinoma, Non-Small-Cell Lung, medicine, Humans, In patient, Duration (project management), business

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54acd87e887272a93e63cf9cd9d9f52dTest
    https://pubmed.ncbi.nlm.nih.gov/33939474Test


    أضف إلى المفضلة
  6. 6
    Analysis of circulating tumor DNA in the phase 2 BTCRC LUN 16-081 trial of consolidation nivolumab with or without ipilimumab after chemoradiation in stage III non–small cell lung cancer

    المؤلفون: Soyeong Jun, Nikhil Shukla, Greg Andrew Durm, Angela B. Hui, Sha Cao, Christian Kunder, Ash A. Alizadeh, Nasser H. Hanna, Maximilian Diehn

    المصدر: Journal of Clinical Oncology. 40:8534-8534

    مصطلحات موضوعية: Cancer Research, Oncology

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::e7eb6b31454570716dbefe104e834743Test
    https://doi.org/10.1200/jco.2022.40.16_suppl.8534Test


    أضف إلى المفضلة
  7. 7
    Physician awareness of immune-related adverse events from checkpoint inhibitors

    المؤلفون: Ahmed Bilal Khalid, Shadia Ibrahim Jalal, Greg Andrew Durm

    المصدر: Journal of Clinical Oncology. 40:6571-6571

    مصطلحات موضوعية: Cancer Research, Oncology

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::31c408120a93b40a57d871c46cf78490Test
    https://doi.org/10.1200/jco.2022.40.16_suppl.6571Test


    أضف إلى المفضلة
  8. 8
    Consolidation nivolumab plus ipilimumab or nivolumab alone following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: BTCRC LUN 16-081

    المؤلفون: Greg Andrew Durm, Hirva Mamdani, Sandra K. Althouse, Salma K. Jabbour, Apar Kishor Ganti, Shadia Ibrahim Jalal, Jason Alan Chesney, Jarushka Naidoo, Borys Hrinczenko, Mary Jo J. Fidler, Ticiana Leal, Lawrence Eric Feldman, Naomi Fujioka, Nasser H. Hanna

    المصدر: Journal of Clinical Oncology. 40:8509-8509

    مصطلحات موضوعية: Cancer Research, Oncology

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::376bab74bf1882e6895e98786b9d7c04Test
    https://doi.org/10.1200/jco.2022.40.16_suppl.8509Test


    أضف إلى المفضلة
  9. 9
    Ezabenlimab (BI 754091), an anti-PD-1 antibody, in combination with BI 836880, a VEGF/Ang2-blocking nanobody, in patients (pts) with advanced colorectal cancer (CRC)

    المؤلفون: Susanna Varkey Ulahannan, Ivor John Percent, Edward Arrowsmith, Maen A. Hussein, Viralkumar K. Bhanderi, John Hamm, Greg Andrew Durm, Damijan Erzen, Prasant Mohanty, David R. Spigel

    المصدر: Journal of Clinical Oncology. 40:98-98

    مصطلحات موضوعية: Cancer Research, Oncology

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::f35e26553d255d0876f791b6cd68b836Test
    https://doi.org/10.1200/jco.2022.40.4_suppl.098Test


    أضف إلى المفضلة
  10. 10
    A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179

    المؤلفون: Bamidele A. Adesunloye, Ebenezer A. Kio, Shadia I. Jalal, Karen L. Reckamp, Michael L. Titzer, Robert M. Langdon, Robin Zon, Greg Andrew Durm, Goetz H. Kloecker, Sandra Althouse, Wael A. Harb, Ryan D. Gentzler, Radhika V. Walling, Ziyue Liu, Nasser H. Hanna, Salma K. Jabbour, Michael J. Williamson, Ahad Ali Sadiq

    المصدر: CancerReferences. 126(19)

    مصطلحات موضوعية: Cancer Research, medicine.medical_specialty, Lung Neoplasms, Programmed Cell Death 1 Receptor, Pembrolizumab, Antibodies, Monoclonal, Humanized, Gastroenterology, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, Carcinoma, Non-Small-Cell Lung, medicine, Clinical endpoint, Humans, 030212 general & internal medicine, Etoposide, Pneumonitis, Aged, Neoplasm Staging, Cisplatin, Aged, 80 and over, business.industry, Chemoradiotherapy, Middle Aged, medicine.disease, Carboplatin, Confidence interval, Pemetrexed, Oncology, chemistry, 030220 oncology & carcinogenesis, business, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70b7cd82bb0ca5ddc5446872bdca4e8dTest
    https://pubmed.ncbi.nlm.nih.gov/32697352Test


    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث